Hinova Pharmaceuticals, Inc. Class ASSE: 688302

"HINOVA PHARMACEUTICALS INC."Voluntary Disclosure Announcement on Receipt of Notice of Approval for Initiation of a Phase III Clinical Trial of Deuterated Enzalutamide Soft Capsules for High-risk Biochemical Recurrence (BCR) Prostate Cancer

· Issued by Hinova Pharmaceuticals, Inc. Class A via Shanghai Stock Exchange
Voluntary Disclosure Announcement on Receipt of Notice of Approval for Initiation of a Phase III Clinical Trial of Deuterated Enzalutamide Soft Capsules for High-risk Biochemical Recurrence (BCR) Prostate Cancer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Hinova Pharmaceuticals, Inc. Class A

All Hinova Pharmaceuticals, Inc. Class A news releases